Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Halozyme Therapeutics, Inc. (HALO) had Weighted-Average Shares Outstanding (Diluted) of 121.22M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$481.00M |
|
$229.91M |
|
$79.17M |
|
$401.83M |
|
$193.34M |
|
$287.65M |
|
$-2.75M |
|
$284.90M |
|
$284.90M |
|
$229.91M |
|
$229.91M |
|
$229.91M |
|
$229.91M |
|
$287.65M |
|
$323.27M |
|
117.27M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
121.22M |
$1.96 |
|
$1.90 |
|
| Balance Sheet Financials | |
$933.02M |
|
$84.27M |
|
$1.64B |
|
$2.58B |
|
$344.44M |
|
$1.94B |
|
$2.09B |
|
$2.43B |
|
$143.54M |
|
$-1.36B |
|
$143.54M |
|
114.04M |
|
| Cash Flow Statement Financials | |
$420.97M |
|
$-65.54M |
|
$-327.86M |
|
$136.42M |
|
$163.99M |
|
$27.57M |
|
$34.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.71 |
|
-- |
|
-- |
|
0.93 |
|
14.95 |
|
83.54% |
|
59.80% |
|
59.80% |
|
-- |
|
59.23% |
|
47.80% |
|
$413.06M |
|
-- |
|
-- |
|
-- |
|
0.19 |
|
0.58 |
|
1.06 |
|
85.29 |
|
160.17% |
|
-16.90% |
|
8.92% |
|
11.05% |
|
$1.26 |
|
$3.41 |
|
$3.47 |
|